Treatment of Relapsed/Refractory Non Hodgkin Lymphoma Patients with Venetoclax Therapy: A Single-Center Evaluation of off-label use

Non-Hodgkin lymphomas (NHL) are a heterogeneous group of diseases which may exhibit aggressive behavior in the relapsed/refractory setting. Venetoclax shows clinical activity in phase I trials for patients with NHL. We investigated 34 patients treated off-study. Outcomes of salvage venetoclax showed a median progression-free survival of 2 months. Challenges of venetoclax therapy in NHL include choice of efficacious combination therapies.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research